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Endovascular stent graft repair for infected
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and Jensen T. C. Poon, MBBS, FRCS, Hong Kong, China
Objective: Open surgical repair for infected thoracic aortic pseudoaneurysms carries significant mortality and morbidity.
Endovascular stent graft repair has been our preferred approach, although its role remains controversial because
persistent infection is always a concern. We aimed to assess the efficacy and durability of endovascular stent graft repair
in these patients.
Methods: Between August 2000 and November 2005, seven consecutive patients with eight infected pseudoaneurysms of
the thoracic aorta were treated with endovascular stent graft repair. Patients were diagnosed based on a typical appearance
of an infected pseudoaneurysm on imaging together with a positive bacteriology culture or clinical evidence of sepsis. The
follow-up protocol included regular clinical examination, hematologic tests, and computed tomography scans.
Results: There were six men and one woman with a median age of 68 years at operation. Three patients presented with an
aortoenteric fistula. The operations were performed in the operating room with the image guidance of a mobile C-arm.
Endovascular stent grafts were deployed successfully in all patients, with complete exclusion of the pseudoaneurysms.
Intravenous antibiotics were continued for 1 to 6 weeks and followed by lifelong maintenance oral antibiotics. The
median hospital stay was 27 days, with no hospital deaths. No paraplegia or other major complications occurred. Two
patients with aortoesophageal fistula where the fistula tracts were persistent died during follow-up. The other five patients
remained well, with no evidence of graft infection at a median follow-up of 34 months. A significant reduction in the
diameter of the pseudoaneurysm (>5 mm) was noted on computed tomography scans after 12 months.
Conclusion: Endovascular stent graft repair is effective and may be a durable option for infected pseudoaneurysms of the
thoracic aorta. ( J Vasc Surg 2006;44:701-5.)Infected pseudoaneurysm of the aorta is a rare but
life-threatening condition. The standard treatment has
been surgery in the form of wide debridement and resec-
tion of the infected aorta and the surrounding tissue,
followed by revascularization via in situ or extra-anatomic
grafting together with long-term antibiotics.1 A significant
hospital mortality rate of up to 40%2,3 has been reported,
resulting from the magnitude of surgery, severe coexisting
medical comorbidities, and patient instability because of
systemic sepsis or rupture.
In the recent decade, endovascular stent graft repair has
been introduced as a less invasive alternative for treating
abdominal aortic aneurysms, with a reduced perioperative
mortality and morbidity.4,5 This treatment strategy has also
been extended to infected pseudoaneurysms of the thoracic
and abdominal aorta,6-9 although failure of endovascular
treatment in such situation resulting in a fatal outcome has
also been reported.10
Endovascular stent graft repair has been our preferred
approach for infected pseudoaneurysms of the thoracic
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sistent infection is always a concern. We assessed the effi-
cacy and durability of endovascular stent graft repair in
these patients.
PATIENTS AND METHODS
Between August 2000 and November 2005, seven
consecutive patients with eight infected pseudoaneurysms
of the thoracic aorta were treated with endovascular stent-
graft repair. Surgical interventions were done to control
sepsis and prevent rupture and bleeding. Patients were
diagnosed based on a typical appearance of an infected
pseudoaneurysm on imaging, including saccular morphol-
ogy arising from a “breach” in the aortic wall (Fig 1) and
rim enhancement over the pseudoaneurysm sac (Fig 2),
together with a positive bacteriology culture or clinical
evidence of sepsis. Patients were regularly reassessed post-
operatively with clinical examination, hematologic tests,
and follow-up computed tomography (CT) scans at 1
month and every 6 months thereafter.
During the same period, two other patients with in-
fected pseudoaneurysms of the thoracoabdominal aorta
received open repair and in situ reconstruction. Endovas-
cular stent grafts were not considered in these two patients
because of the involvement of the visceral branches requir-
ing bypasses. Both patients survived, although acute renal
failure developed in one as a result of a thrombosed renal
bypass graft requiring re-exploration and redo bypass.
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the bacteriology, surgical outcome, and follow-up data
were prospectively collected.
RESULTS
There were six men and one woman with a median age
of 68 years (range, 37 to 90 years) at operation. One patient
had two synchronous infected aortic pseudoaneurysms.
The demographic data and the medical comorbidities are
listed in Table I.
Presentation and pathology. Three patients pre-
sented with an aortoenteric fistula. An 87-year-old man had
an infected thoracic aortic pseudoaneurysm with aortoe-
sophageal fistula presenting with massive hematemesis. The
other two patients had carcinoma of the esophagus. One
had undergone esophagectomy with jejunal loop recon-
Fig 1. Computed tomography scan shows a typical infected pseu-
doaneurysm over the lower thoracic aorta (arrow).
Fig 2. Computed tomography scan shows a typical infected tho-
racic aortic pseudoaneurysm. Note the contrast-enhanced pseudo-
aneurysm sac (arrow).struction. Anastomotic leakage developed, and he pre-sented 4 weeks after the esophagectomy with a mediastinal
abscess and an infected thoracic aortic pseudoaneurysm,
with subsequent aortojejunal fistula and massive hemate-
mesis. The remaining patient had an inoperable carcinoma
of the esophagus and an aortoesophageal fistula developed
after chemoirradiation. The other four patients had primary
infected aortic pseudoaneurysms.
Apart from the typical appearance on imaging (Figs 1
and 2), positive blood cultures were obtained in three
patients (one methicillin resistant Staphylococcus aureus,
one methicillin sensitive S aureus, and one Salmonella
enteritidis). Salmonella infection was established in one
patient by a positive Widal test result. Candida albicans
was found to be the pathogen in another patient, as dem-
onstrated by tissue culture obtained after subsequent tho-
racotomy and mediastinal debridement (Table I).
Surgical management and perioperative outcome.
Intravenous antibiotics were started once the diagnosis of
infected aortic pseudoaneurysm was made. Patients with
Salmonella infection were treated with ceftriaxone, 1 to 2 g
every 12 hours. For patients with non-Salmonella infec-
tions, antibiotics were determined by culture results and
sensitivity testing if available, with consultation with the
microbiologist.
All the procedures were performed in the operating
room, with six under general anesthesia and one with local
anesthetic agents. With the image guidance of a mobile
C-arm (Philips BV-29, Philips Medical System, The Neth-
erlands) or OEC 9800 (General Electric Company, Fair-
field, Conn), endovascular stent grafts were deployed suc-
cessfully in all patients, with complete exclusion of the
pseudoaneurysms. The type and size of the endografts used
are listed in Table II.
In the three patients with aortoenteric fistula, hemate-
mesis stopped immediately after the operation. Subsequent
Table I. The demographic data, medical comorbidities
and the pathology of the patients with infected
pseudoaneurysms of the thoracic aorta
Patient Sex/Age
Medical
comorbidities Organisms Rupture
1 M/87 AF MRSA AEF
2 M/37 HT, CRF MSSA No
3* M/59 HT, DM, IHD,
COAD
Salmonella
enteritidis
No
4 M/68 CaE† Candida albicans AJF
5 M/77 COAD Salmonella No
6 M/59 Inoperable CaE — AEF
7 M/90 AF, HT, DM — No
AF, Atrial fibrillation; CaE, carcinoma of the esophagus; COAD, chronic
obstructive airway disease; CRF, chronic renal failure requiring dialysis;
DM, diabetes mellitus; HT, hypertension; IHD, ischemic heart disease;
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-
sensitive Staphylococcus aureus; AEF, aortoesophageal fistula; AJF, aor-
tojejunal fistula.
*The patient with two infected aortic pseudoaneurysms.
†This patient had post-esophagectomy anastomotic leakage.thoracotomy with mediastinal debridement was required in
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control the sepsis. The fistula in this patient subsequently
closed with endoscopic injection of fibrin sealant directly
into the fistula tract. We have previously reported this novel
approach of combined endovascular stenting and endo-
scopic injection of fibrin sealant in the management of
aortojejunal fistula.11
Intravenous antibiotics were then continued for 1 to 6
weeks and followed by lifelong maintenance oral antibiotics
(Table II). There was no hospital death. The median hos-
pital stay was 27 days (range, 11 to 105 days). Two patients
stayed in the hospital for 2 months (Table II). In the
patient with aortojejunal fistula and subsequent mediastinal
debridement, prolonged hospital stay was required for daily
irrigation of the mediastinal abscess via the tubal drain
inserted until the fistula healed. Another patient stayed
3 months because of placement issues and arrangement
of continued hemodialysis, which she required before
admission. No paraplegia or other major complications
occurred.
Follow-up. There were two deaths at follow-up
(Table II). The 87-year-old man who had a thoracic aortic
pseudoaneurysm with aortoesophageal fistula refused fur-
ther definitive surgical intervention after stabilization with
endovascular stent graft repair. He died from sepsis 3
months after the initial procedure. The patient with aortoe-
sophageal fistula who had inoperable carcinoma of the
esophagus died 3 months later as a result of stent graft
infection and presented with recurrent hematemesis. The
other five patients remained well, with no evidence of graft
infection at a median follow-up of 34 months (range, 4 to
38 months).
Follow-up CT scans were performed in all patients.
Thrombosis of the pseudoaneurysm sac was noted, and no
evidence of late graft infection was detected. A significant
reduction in the diameter of the pseudoaneurysm sac (5
Table II. Perioperative details, duration of follow-up, and
Patient Endovascular repair*
Hospital sta
(days)
1 AneuRx 36/120 36
2 Talent 32/100 105
3‡ Talent 32/100
Talent§ 30/26/113 27
4 Talent 32/115 81
5 Zenith 34/152 11
6 Zenith 34/77 19
7 Zenith 30/120 11
AneuRx and Talent (Medtronic AVE Inc, Santa Rosa, Calif); Zenith, (Coo
*Dimension of endografts shown in diameter/length in mm.
†Deaths at follow-up.
‡The patient with two infected aortic pseudoaneurysms.
§Tapering graft.mm) was observed after 12 months (Fig 3).DISCUSSION
Endovascular stent graft repair has provided a viable,
less-invasive alternative in the management of aortic dis-
eases. Favorable results with reduced perioperative mortal-
ity and morbidity have been reported in endovascular repair
of abdominal aorta aneurysms.4,5 Its application has also
been extended to the treatment of infected aortic pseudoa-
neurysms.6-9 Stanley et al7 reported successful endovascu-
lar treatment of four patients with mycotic thoracic aortic
aneurysms, and successful endovascular repair with com-
plete regression of an infected abdominal aortic aneurysm
has also been documented.6
A less-invasive approach may be particularly appealing
in our patients who had thoracic aortic involvement. As
shown by Moneta,12 the operative mortality is much higher
in patients with mycotic aneurysms involving the suprarenal
or thoracic aorta compared with infrarenal involvement
(43% vs 10%). Endovascular stent graft repair obviates the
need for thoracotomy, significant blood loss, aortic cross-
clamping, and extracorporeal circulation in these already
critically ill patients. This is well illustrated in this series of
seven patients, where the technical success was 100% with
no hospital deaths.
There has always been a concern about persistent infec-
tion by putting a stent graft in an infected field. In situ
prosthetic reconstruction was often unavoidable, however,
even with open repair. The safety, durability, and efficacy of
in situ reconstruction in the presence of aortic sepsis have
been described.13,14 Chan13 reported 22 mycotic aortic
aneurysms (including 21 with thoracic/suprarenal involve-
ment) treated with in situ prosthetic graft reconstruction.
Nineteen patients (86%) survived for periods ranging from
3 months to 8 years postoperatively, with only one recur-
rent graft infection.
Long-term follow-up (30 months) data were avail-
able in three of our patients with four infected aortic
lifelong maintenance antibiotics prescribed
Follow-up duration
(months) Antibiotics (daily)
3† —
38 Cephalexin 500 mg
35 Levofloxacin 500 mg
34 Fluconazole 200 mg,
Metronidazole 400 mg,
Cephalexin 500 mg 3
7 Levofloxacin 250 mg
3* —
4 Clindamycin 450 mg 3
omington, Ind).the
y
k, Blopseudoaneurysms treated by endovascular means. There
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CT scans showed exclusion of the pseudoaneurysms with
significant reduction in the sac size. We believe that potent
antibiotics, together with lifelong maintenance, are essen-
tial because of the definite risk of graft contamination
during implantation. In addition, regular surveillance with
CT scans is also indispensable.
On the other hand, the risk of persistent infection may
be important in the situation where sepsis and contamina-
tion is ongoing, such as in the presence of an aortoesopha-
geal fistula. Owing to the persistent esophageal contamina-
tion, a poor outcome is not unexpected without further
definitive surgery. This is well exemplified by the two
follow-up deaths in this series. Both patients had a persis-
tent esophageal lesion resulting in continued contamina-
tion of the stent-grafts. Both patients died of graft infection
and hematemesis 3 months after the initial stent graft
placement. This underscores the importance of eliminating
continued graft contamination. As shown in the patient
with aortojejunal fistula secondary to esophagojejunal anas-
tomotic leakage, long-term survival is possible if the fistula
heals.
Even in situation where the contamination cannot be
controlled, endovascular repair can at least be used as a
temporary measure to save the patient from exsanguinating
hematemesis before definitive surgery. Successful manage-
ment of an aortoesophageal fistula secondary to mycotic
thoracic aortic aneurysm using endovascular repair, fol-
lowed by subsequent definitive esophagectomy has been
reported.15
Open repair of thoracic aortic pathologies always incurs
a considerable risk of postoperative paraplegia. In the re-
view of their extensive experience, Svensson et al16 reported
a significant 16% incidence of paraplegia/paraparesis in a
series of 1500 patients undergoing thoracoabdominal
aortic repairs. With the absence of aortic cross-clamping,
Fig 3. Serial computed tomography scan in the pat
methicillin-sensitive Staphylococcus aureus after endovas
pseudoaneurysm.endovascular stent graft repair has a theoretic benefit ofminimizing the ischemic injury to the spinal cord and hence
decreased the risk of paraplegia.17 This was well shown by
the absence of paraplegia/paraparesis in our patients.
Although randomized controlled trials may be the ul-
timate answer to the role of endovascular stent graft repair
in infected aortic pseudoaneurysms, a sufficient number for
a trial may be impossible given with the rarity of this entity.
Case series such as this with longer-term follow-up data
may be helpful in defining the role of endovascular repair in
this difficult clinical situation.
CONCLUSION
Endovascular stent graft repair is effective and may be a
durable option for patients with infected pseudoaneurysms
of the thoracic aorta. Even for patients in whom sepsis
cannot be adequately controlled, it may serve as a tempo-
rary measure to save life before definitive surgery.
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